Centre bans 16 Fixed Dose Combination drugs over safety and efficacy risks
Synopsis
India's Health Ministry has immediately banned 16 Fixed Dose Combination drugs — spanning painkillers, antibiotics, and dermatological products — after a Supreme Court-directed expert review found them irrational and potentially harmful. It is the latest in a decade-long regulatory push to purge scientifically unjustified drug combinations from the Indian market.
Key Takeaways
The Ministry of Health and Family Welfare banned 16 Fixed Dose Combination (FDC) drugs with immediate effect on 20 June .
The ban was imposed under Section 26A of the Drugs and Cosmetics Act, 1940 , following a Supreme Court directive for a comprehensive FDC review.
The Drugs Technical Advisory Board (DTAB) Expert Committee found all 16 FDCs lacked adequate therapeutic justification and posed potential health risks.
Affected categories include dermatological products , pain-relief and antispasmodic drugs , and antibiotic-based formulations .
All State Drug Controllers , manufacturers, importers, and distributors have been directed to implement the ban and discontinue affected products immediately.
The Ministry of Health and Family Welfare on Saturday, 20 June prohibited the manufacture, sale, and distribution of 16 Fixed Dose Combination (FDC) drugs for human use across India, citing inadequate therapeutic justification and potential health risks. The ban takes effect immediately under Section 26A of the Drugs and Cosmetics Act, 1940.
Why the Ban Was Imposed
The move follows directions from the Supreme Court of India, which had ordered a comprehensive review of FDCs available in the Indian market. Acting on those directions, the Drugs Technical Advisory Board (DTAB) constituted a dedicated Expert Committee to evaluate the safety, efficacy, and therapeutic value of these combinations.
After a detailed scientific assessment, the Expert Committee concluded that all 16 FDCs lacked adequate therapeutic justification and that their continued availability posed potential health risks to patients. The government determined that the risks associated with these combinations outweighed any possible clinical benefit.
Which Drug Categories Are Affected
The prohibited formulations span multiple therapeutic categories, including certain dermatological products, pain-relief and antispasmodic drugs, and antibiotic-based formulations. The Ministry stated that these combinations were found to be irrational and unsupported by sufficient scientific evidence — a standard regulatory threshold for FDC prohibition in India.
Notably, this is not the first such action. The government has previously banned hundreds of FDCs in waves — most significantly in 2016, when over 340 combinations were prohibited following a similar DTAB-led review process, and again in subsequent years. The latest order continues that pattern of evidence-based regulatory enforcement.
Implementation and Compliance Directives
The Health Ministry has directed all State Drug Controllers, regulatory authorities, and enforcement agencies to strictly implement the ban and ensure compliance with immediate effect. Manufacturers, importers, distributors, and other stakeholders have been advised to discontinue the affected products and align with the provisions of the law.
What the Government Said
The Ministry emphasised that the action reinforces the government's commitment to evidence-based healthcare and the rational use of medicines. It underscored that only safe, effective, and scientifically validated medicines should be available to the public — a principle that has guided successive rounds of FDC rationalisation in India.
With the notifications now in force, the ban on all 16 FDCs is nationwide and unconditional. Regulators and industry will be closely watched for the speed of compliance, particularly in states where enforcement of earlier FDC bans faced delays.
Point of View
Yet the pace of enforcement remains uneven — the 2016 mass ban of over 340 combinations faced prolonged court challenges and patchy state-level compliance. The fact that the Supreme Court had to direct this latest review, rather than it arising from proactive regulatory initiative, is itself a signal of institutional inertia. The deeper question is whether banning combinations after they have been manufactured and sold for years adequately protects patients, or whether the pre-approval gatekeeping for new FDCs needs to be fundamentally tightened. Without a public, searchable list of the specific 16 banned combinations, patients and pharmacists cannot act on the notification — transparency here is not optional.
NationPress
20 Jun 2026
Frequently Asked Questions
Which 16 drugs have been banned by the Centre?
The Ministry of Health and Family Welfare has prohibited 16 Fixed Dose Combination (FDC) drugs spanning dermatological products, pain-relief and antispasmodic formulations, and antibiotic-based combinations. The government has not yet released a publicly named list of all 16 products in the available notification summary; the full schedule is contained in the official gazette notification issued under Section 26A of the Drugs and Cosmetics Act, 1940.
Why has the Centre banned these FDC drugs?
The ban follows a Supreme Court-directed review by the Drugs Technical Advisory Board (DTAB) Expert Committee, which found that all 16 combinations lacked adequate therapeutic justification and that their continued use posed potential health risks. The government concluded that the risks outweighed any clinical benefit.
What is a Fixed Dose Combination (FDC) drug?
A Fixed Dose Combination drug is a formulation that contains two or more active pharmaceutical ingredients combined in fixed proportions in a single dosage form. While some FDCs are clinically rational and widely used, others combine ingredients without sufficient evidence that the combination offers benefits over individual drugs.
When does the FDC ban come into effect?
The ban came into effect immediately upon issuance of the notification on 20 June. Manufacturers, importers, and distributors have been directed to discontinue the affected products without delay.
Is this the first time India has banned FDC drugs?
No. India has undertaken multiple rounds of FDC prohibition, most notably in 2016 when over 340 combinations were banned following a similar DTAB-led expert review. The latest action continues a long-standing regulatory effort to remove irrational drug combinations from the Indian market.
